Warning over 'intractable problem' as Australia's fire ant fight faces critical moment
Native to South America, they have well and truly spread north, invading more than a dozen US states and costing the country's economy billions of dollars a year. They've caused havoc on golf courses, private properties and even led to reported deaths in Florida and Texas from severe allergic reactions.
A report in USA Today last month even detailed how two species of the invasive ant are crossbreeding, creating an even nastier and hardier bug.
It's a bleak picture Australia is desperately hoping to avoid.
Mark Hoddle, an entomologist and biological control specialist, has spent years studying fire ants at the University of California. He warns Australia must urgently act to stop them from becoming a permanent fixture of the landscape.
"Some entomologists have referred to this perpetual insecticidal war and management plan against fire ants in the US as the Vietnam of entomology. It just seems like an intractable problem," he told ABC radio on Friday.
At least in the United States, where they have been for about a century, the prospect of eradication is probably futile, he warned.
"It will probably never be winnable with the technology we are currently using," he said.
Related: Five colonies of yellow crazy ants detected in Queensland holiday spot
According to experts in Australia at the Invasive Species Council (ISC) and the National Fire Ant Eradication Program, if left unchecked the so-called super pest could make itself at home across 97 per cent of the continent, given our climate's suitability to the species. Ultimately, they could do more damage than cane toads, camels, foxes and feral pigs combined.
After recent discoveries of fire ants in Queensland, including on one Scenic Rim property where they were found "chewing" on a lawn mower, authorities are urging residents to be vigilant and take precautions.
"Fire ants are great stowaways, and they love to get into organic material in particular," Reece Pianta from the ISC told Yahoo News this week. "Empty out the catcher of your mower," he urged. "Don't leave the clippings in there, and clean it down. It's also good advice to clean things that are being moved from place to place."
Agricultural minister spruiks nation's biosecurity efforts
The federal government is set to contribute some $296 million over the next four years to help fight the fire ant invader, with more money tipped in by the states.
Julie Collins, the federal Minister for Agriculture, on Friday hit back at her Coalition counterpart who on Thursday said the federal government wasn't doing enough to stop the spread.
"What I would say is that Australia has been quite successful in terms of trying to contain the red imported fire ants compared to how other countries are dealing with it. We have managed to contain the spread of it compared to other countries," he said.
In particular, she highlighted the federal government's collaboration with the states as well as efforts to engage the community to raise awareness about the threat, saying biosecurity "is everyone's responsibility".
"Part of the program has been the public awareness campaign and making sure that people understand what they are," she said.
The federal government is coming under increased pressure to make public the National Fire Ant response plan for 2023 to 2027, which is currently a 'cabinet in confidence' document. The minister would not be drawn on whether it would be made public.
"What I'd say is the significant new funding that we have provided to date has allowed the program to expand its reach," she said. "It's put on 350 new workers. There's a new depot, there's new vehicles, new aerial eradication contracts. There's baiting going on. It's doubled the size of the treatment and surveillance area in terms of the existing outbreaks in Australia. We are taking this incredibly seriously."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Private conversations with Albert Einstein published as book
Records from Albert Einstein's final years are being published as a book around 20 years after their discovery, as transcripts of telephone conversations the physicist had between 1953 and 1955, publisher Heyne Verlag announced on Monday. The records by Johanna Fantova, considered to be Einstein's last close female friend, describe events from the last year and a half before the scientist's death at the age of 76. Einstein (1879-1955), who fled Nazi Germany for the United States in 1933, reportedly shared his daily experiences in US exile with Fantova over the phone. Fantova, who first met Einstein in Germany but also moved to the US, transcribed his statements with his consent, the publisher said. The 62-page typescript in German was discovered by chance in 2004 at the Firestone Library of Princeton University, where Fantova once worked as a curator. The materials lay unprocessed in the archive for a long time. The diary entries are now set to be published for the first time in an annotated edition with additional findings on September 24. The title of the book by Peter von Becker is: "I am a Magnet for All the Maniacs. The Einstein Transcripts – His Life, His Last Love, His Legacy." In the diary, Einstein - who revolutionized physics with his Theory of Relativity - shares his thoughts on politics, science, everyday life and love. For instance, he criticized the arms race of the superpowers and the rearmament of Germany, and commented on the conflict between Israelis and Palestinians, according to the publisher. Solve the daily Crossword
Yahoo
3 hours ago
- Yahoo
Could cancer drugs be the future of Alzheimer's treatment?
With few treatments available to stop or reverse Alzheimer's disease, scientists have turned to cancer drugs as a potential means of walking back cognitive decline. Alzheimer's cases are rising in the United States and worldwide due to an aging population, but there is no cure for the disease. Attempts to develop new treatments that slow the disease's progress, rather than lessen symptoms, have frequently failed. Only two drugs — the antibody therapies Leqembi and Kisunla — are currently approved by the Food and Drug Administration to slow the progression of early Alzheimer's, and scientists say their benefits are limited. Some pharmaceutical companies have halted or abandoned their Alzheimer's drug development programs because of unsuccessful trials. Others are trying to use existing medications, including popular weight loss drugs, to combat Alzheimer's. With that in mind, researchers at the University of California, San Francisco conducted a broad search for drugs that could be repurposed to treat the condition — in theory, reducing the time in which the drugs could be made available to patients. They scoured a database of more than 1,300 drugs of various classes, including antipsychotics, antibiotics, antifungals and chemotherapy drugs. Then, they looked at how those drugs affected gene expression. Their new study, published Monday in the journal Cell, identified two cancer drugs as the best candidates to lower Alzheimer's risk in patients. When combined, the drugs seemed to slow or reverse Alzheimer's symptoms in mice. One of the drugs is normally used to treat breast cancer, while the other is effective against colon and lung cancer. Alzheimer's disease is associated with significant changes in the way genes are expressed in the brain, leading to the increased production of certain proteins and the decreased production of others. These imbalances may disrupt brain function and contribute to symptoms like memory loss. Fewer than 90 drugs in the researchers' database reversed the expression of signature Alzheimer's-related genes in human brain cells. And five drugs in particular seemed to lower the risk of Alzheimer's in actual patients, based on electronic medical records. The authors ultimately selected two of those drugs, both approved by the FDA to treat cancer, to test in mice. 'We didn't expect cancer drugs to come up' as the most promising, said Marina Sirota, a co-author of the study and interim director of the UCSF Bakar Computational Health Sciences Institute. The authors said the breast cancer drug letrozole seemed to change gene expression in nerve cells. And the colon and lung cancer drug irinotecan seemed to change gene expression in glial cells, which support the nervous system. Alzheimer's can destroy nerve cells and cause glial cells to proliferate, creating inflammation in the brain. In a 2020 study, breast cancer patients who received letrozole were less likely to develop Alzheimer's than patients who did not receive the drug. Colorectal cancer survivors treated with irinotecan also had a decreased Alzheimer's risk, according to a 2021 study. After testing the drugs in mice, the study authors found that the two-drug combo reversed brain degeneration and improved memory in mice that had developed hallmarks of Alzheimer's as they aged. Because results in mice often don't translate to humans, the researchers hope to test the drugs in a clinical trial with Alzheimer's patients. 'Developing a new drug can take hundreds of millions, or even billions, of dollars, on average take more than 10 years. For this repurposed drug, usually it just takes two or three years, and then you can go to the clinical trial and the cost is much, much lower,' said Dr. Yadong Huang, a co-author of the study and professor of neurology at UCSF. 'We still haven't generated or produced any very effective drugs that can really slow dramatically the cognitive decline,' he added. Part of the difficulty in developing drugs for Alzheimer's is the complexity of the disease. Its exact cause is largely unknown. For now, the authors said, it's unclear exactly why the cancer drugs seem to work against Alzheimer's. One theory is that the breast cancer drug blocks the production of estrogen, a hormone that controls the expression of a large number of genes. The colon and lung cancer drug may also block inflammation in the brain by preventing the proliferation of glial cells — though Huang said there are other possibilities. Dr. Melanie McReynolds, an assistant professor of biochemistry at Pennsylvania State University, who was not involved in the study, offered another theory. Her research has suggested that a different type of cancer drug could help treat Alzheimer's by regulating glucose metabolism, the process by which cells make energy. McReynolds said the process is necessary for various brain cells to communicate with each other. 'With aging, with stress, with diseases, that line of communication is disrupted,' she said. McReynolds said the drug combo tested in the new study might reverse metabolic decline — what she called 'the secret for contributing to better outcomes with Alzheimer's.' But assessing how Alzheimer's patients tolerate the combination of cancer drugs will be important. Letrozole can cause hot flashes and irinotecan can cause severe diarrhea. Both drugs can lead to nausea and vomiting. 'These drugs have huge side effects, so you need to always balance and figure out whether those types of side effects would be amenable to somebody with Alzheimer's,' Sirota said. 'It's not that it's a slam dunk.' This article was originally published on Solve the daily Crossword
Bloomberg
4 hours ago
- Bloomberg
Trump's Critical Minerals Obsession Reignites Deep-Sea Mining
By The leader of one of the most aggressive seabed mining startups spent years invoking global warming to spark interest in extracting avocado-sized rocks rich in electric-vehicle battery metals from the bottom of the ocean. 'We want to help the world transition away from fossil fuels with the smallest possible climate change and environmental impact,' Gerard Barron, the Australian chief executive officer of a company then known as DeepGreen, told a 2019 meeting of the United Nations-affiliated International Seabed Authority, which for a decade has been debating regulations to allow the mining of untouched, biodiverse deep-sea ecosystems in global waters.
